Our leadership

Søren Tulstrup is President and Chief Executive Officer (CEO) of Hansa Biopharma, based in Lund Sweden. He has over 30 years of industry experience in a variety of leadership and commercial roles both in-market and globally.  Prior to joining Hansa in 2018, he was CEO at Vifor Pharma, and Santaris Pharma, and held leadership roles at Merck and Sandoz (then acquired by Novartis). Søren Tulstrup has a strong track record of managing the development, launch and growth of biopharmaceuticals globally for the treatment of rare diseases. He also serves as board director and advisor to numerous life science companies across Europe, North America, and emerging markets.  He holds a Master of Science, Economics and Business Administration from Copenhagen Business School and Kellogg Graduate School of Management, Northwestern University. Søren Tulstrup is a graduate of the Royal Danish Army Combat school and has served as an armored infantry officer in the Royal Danish Army. 

Anne Säfström Lanner is Chief Human Resources Officer of Hansa Biopharma, based in Lund, Sweden, since June 2020, previously serving as Vice President Global Human Resources from 2019.  Before joining Hansa, she served in various senior roles at the European Spallation Source (ESS), a multi-disciplinary research facility based on the world’s most powerful neutron source. Prior to that, Anne Säfström Lanner was Head of Human Resources at Cellavision AB (STO:CEVI). 
Anne Säfström Lanner has held positions as Head of HR, Head of Resourcing, HR Manager & Deputy Head of HR and has extensive experience from fast growing start-up international companies.  She holds a Bachelor of Social Science in Human Resource Management, focusing on strategic organizational development & leadership, from Lund University.

Hitto Kaufmann has served as Chief Scientific Officer and then Chief R&D Officer at Hansa Biopharma, Lund, Sweden, since December 2023. Hitto has over 20 years’ experience as biopharma leader in the development of approximately 100 biological therapeutic entities, advancement of strategic R&D partnerships, and building of next generation therapeutic platforms. Prior to joining Hansa, Hitto served as Chief Scientific Officer at Pieris Pharmaceuticals, including leading the R&D site of Pieris in Munich. Before his tenure at Pieris, Hitto held several executive positions at Sanofi and Boehringer Ingelheim
He currently serves as a member of the Scientific Advisory Board of Instituto de Biologia Experimental e Tecnologica (iBET). Hitto began his career as a Research Scientist at the Walter and Eliza Hall Institute in Melbourne. He holds a Ph.D. in Natural Science, from the Swiss Federal Institute of Technology in Zurich.

Shareholding:
Share rights: 130,000
ESOP's: 160,000

Evan Ballantyne is Chief Financial Officer at Hansa Biopharma based in Lund, Sweden. Evan has over 30 years of international financial and operational experience as a senior financial executive in both public and private life science companies.  Prior to joining Hansa in 2024, he served as CFO at Gain Therapeutics, Inc., OncXerna Therapeutics, Inc., Agenus and Clinical Data among others. Evan has held roles of increasing responsibility at biotech, medical technology and information services companies throughout Europe and the US, helping these companies navigate complex financial markets and secure funding and capital to support their growth. Evan has a degree in Honors Business Administration from the University of Windsor, Ontario, Canada as well as a BA in American History & Political Science from the University of Western Ontario, Canada. He is an independent board member of Preveceutical Medical, Inc in Vancouver, British Columbia, Canada.

Shareholding: -
Share rights: 70,000
ESOs: 90,000

Peter Nicklin has more than 30 years of extensive experience and background in the pharmaceutical and healthcare sector in both developed, as well as emerging markets and significant experience in leading global teams. Chair of the Board at Tunstall Healthcare and Sciensus. Previously, CEO and member of the Board of Amann Girrbach AG, Corporate Vice President and EMEA President of Baxter International (NYSE: BAX), as well as senior executive roles at Bayer Healthcare (XETRA: BAYN), Novartis (SWX: NOVN) and Bristol-Myers Squibb (NYSE:BMY). Peter holds a Bachelor of Arts with Honours in Finance from Lancaster University. He is also a Chartered Accountant having qualified at PriceWaterhouseCoopers in London.

Member and chair of the Board since 2022, member of the Remuneration Committee, the Scientific Committee and the US Committee. Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.
Shareholding: 24,500

Eva Nilsagård is the founder and Chief Executive Officer of Nilsagård Consulting AB. Previous interim Chief Financial Officer of various companies, including OptiGroup AB, Plastal, and Vitrolife AB. She has also served in various senior positions at the Volvo Group, or Volvo, including Senior Vice President Strategy & Business Development. Earlier in her career, Eva also held senior positions in finance and business development at AstraZeneca plc and AB SKF. Board member and chair of the audit committee of SEK (Swedish Export Credit Company), AddLife, Bufab Group, Irras AB, Nimbus Group AB, Nanexa, Ernströmgruppen and Xbrane Biopharma, the chair of Spermosens AB, and board member of eEducation Albert AB. Eva has more than ten years of
experience as a mentor for young female managers with high potential. She holds an Executive M.B.A. in Economics and a B.Sc. in accounting and finance from School of Business, Economics and Law in Gothenburg.

Member of the Board since 2019 and chair of the Audit Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: 3,000

Shareholding: 1,000

Hilary Malone has over 25 years of experience in global drug development, regulatory and government affairs, manufacturing and commercialization within the pharmaceutical industry. She has served as Chief Executive Officer of a private life sciences company in start-up phase since November 2021. She previously served as Chief Operating Officer and Executive Vice President at Valo Health Inc., and as the Chief Regulatory Officer and Senior Vice President & Head of Global Regulatory Affairs at Sanofi Inc. (subsidiary of Sanofi SA). Previous experience also includes senior regulatory and drug development roles at Reata Pharmaceuticals, Inc., Pfizer Inc., Wyeth, LLC (acquired by Pfizer Inc.), AstraZeneca plc and GlaxoSmithKline plc. Hilary has also served on the board of Inhibikase Therapeutics. She holds a Ph.D. in Molecular Neuropharmacology and a B.Sc. in Physiology from the University of Dundee, Scotland. She is a U.S., U.K., and Irish citizen.

Member of the Board since 2021, chair of the US Committee, and member of the
Scientific Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma.

Shareholding: -

Anders Gersel Pedersen has over 33 years of experience in the international pharmaceutical industry. Served in various roles at H. Lundbeck A/S in Denmark (CSE: LUN), including most recently as Executive Vice President of Research & Development, as responsible for the discovery and development of the product pipeline from preclinical activities to post-launch marketing studies. Prior to that, served in various roles at Eli Lilly and Company, including most recently as a director overseeing worldwide clinical research in oncology. Anders is Chairman at Aelis and Deputy Chair at Bavarian. Serves on the supervisory boards of Avillion LLP, Bavarian Nordic A/S, AELIS Farma SA, and Genmab A/S. He received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a B.Sc. in Business Administration from Copenhagen Business School.

Member of the Board since 2018, chair of the Scientific Committee, and member of the Remuneration Committee.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa

Shareholding: 2,500

Jonas Wikström has extensive experience in the finance industry where he was a fund manager at Catella Fondförvaltning, as founder and CEO for WR Capital, and from leading positions at ABG Sundal Collier and Alfred Berg. Jonas is currently chairman of the board at Oxe Marine (publ) and chairman of Ramblin Brands Ltd. He holds a Bachelor’s degree in finance from the University of Uppsala and Certified Financial Analyst from the Stockholm School of Economics.

Member of the Board since 2024.
Independent of Hansa Biopharma and its executive management. Independent of major shareholders of Hansa Biopharma

Shareholding: 361,301

Florian joined Redmile in May 2022 working as a Managing Director. From 2015 to 2022, Florian was the founding CEO of Concilio, a digital medical concierge service. Previous experiences include the role of managing partner and co-head of the healthcare team at Innovation Capital, a Paris-based VC (2008-2015); CFO of DBV technologies (2007-2008), where he had co-led the investment while at Apax Partners (2003-2007); and in the Healthcare Research Team at Citigroup. Prior to these experiences, Florian worked as an emergency physician in the UK and in France. Florian is Member of the boards of Sensome (French private Medtech company), Home Biosciences (French private venture builder), Scancell (UK-based biopharmaceutical company), and Sensorion (board observer, French Euronext-Growth listed biotech). He graduated with a Distinction in Medicine from Imperial College, London, and holds a BA (hons) in physiology from Oxford University.

Member of the Board since 2024.
Independent of Hansa Biopharma and its executive management.

Shareholding: No direct and indirect holdings.